DNA interstrand crosslink repair and cancer

Nature Reviews Cancer

Volumn 11, Issue 7, 2011, Pages 467-480

  Deans, Andrew J ^a,b   West, Stephen C ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; MELPHALAN; MITOMYCIN C; OXALIPLATIN; PICOPLATIN; PSORALEN; PYRROLOBENZODIAZEPINE DERIVATIVE; SATRAPLATIN; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER THERAPY; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DNA CROSS LINKING; DNA REPAIR; ESOPHAGUS CANCER; FANCONI ANEMIA; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NEOPLASM; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCYTOPENIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; TESTIS CANCER; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CROSS-LINKING REAGENTS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA; HUMANS; NEOPLASMS; RECOMBINATION, GENETIC;

EID: 79959635260     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3088     Document Type: Review

References (169)

1. Goodman, L. S. et al. Nitrogen mustard therapy. Use of methyl-bis(β-chloroethyl)amine hydrochloride and tris(β-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J. Am. Med. Assoc. 132, 126-132 (1946).
2. Eastman, A. Reevaluation of interaction of cis-dichloro(ethylenediamine) platinum(II) with DNA. Biochemistry 25, 3912-3915 (1986). (Pubitemid 16042519)
3. Gargiulo, D., Kumar, G. S., Musser, S. S. & Tomasz, M. Structural and function modification of DNA by mitomycin C. Mechanism of the DNA sequence specificity of mitomycins. Nucleic Acids Symp. Ser. 169-170 (1995).
4. Kozekov, I. D. et al. DNA interchain cross-links formed by acrolein and crotonaldehyde. J. Am. Chem. Soc. 125, 50-61 (2003). (Pubitemid 36068643)
5. Stone, M. P. et al. Interstrand DNA cross-links induced by α, β-unsaturated aldehydes derived from lipid peroxidation and environmental sources. Acc. Chem. Res. 41, 793-804 (2008).
6. Brooks, P. J. & Theruvathu, J. A. DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. Alcohol 35, 187-193 (2005). (Pubitemid 41079922)
7. Folmer, V., Soares, J. C., Gabriel, D. & Rocha, J. B. A high fat diet inhibits δ-aminolevulinate dehydratase and increases lipid peroxidation in mice (Mus musculus). J. Nutr. 133, 2165-2170 (2003). (Pubitemid 36841533)
8. Ljunggren, B. Severe phototoxic burn following celery ingestion. Arch. Dermatol. 126, 1334-1336 (1990). (Pubitemid 20344617)
9. Manderfeld, M. M., Schafer, H. W., Davidson, P. M. & Zottola, E. A. Isolation and identification of antimicrobial furocoumarins from parsley. J. Food Prot. 60, 72-77 (1997). (Pubitemid 27114819)
10. Ashwood-Smith, M. J., Poulton, G. A., Barker, M. & Mildenberger, M. 5-Methoxypsoralen, an ingredient in several suntan preparations, has lethal, mutagenic and clastogenic properties. Nature 285, 407-409 (1980). (Pubitemid 10047222)
11. Dutta, S., Chowdhury, G. & Gates, K. S. Interstrand cross-links generated by abasic sites in duplex DNA. J. Am. Chem. Soc. 129, 1852-1853 (2007).
12. Bennetts, L. E. et al. Impact of estrogenic compounds on DNA integrity in human spermatozoa: evidence for cross-linking and redox cycling activities. Mutat. Res. 641, 1-11 (2008).
13. Dunnick, J. K., Forbes, P. D., Davies, R. E. & Iverson, W. O. Toxicity of 8-methoxypsoralen, 5-methoxypsoralen, 3-carbethoxypsoralen, or 5-methylisopsoralen with ultraviolet radiation in the hairless (HRA/Skh) mouse. Toxicol. Appl. Pharmacol. 89, 73-80 (1987). (Pubitemid 17106657)
14. Sanderson, B. J. & Shield, A. J. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat. Res. 355, 41-57 (1996). (Pubitemid 26275503)
15. Pechura, C. M. & Rall, D. P. Veterans at Risk: The Health Effects of Mustard Gas and Lewisite (National Academy Press, Washington D. C., 1993).
16. Tucker, M. A., Coleman, C. N., Cox, R. S., Varghese, A. & Rosenberg, S. A. Risk of second cancers after treatment for Hodgkin's disease. N. Engl. J. Med. 318, 76-81 (1988). (Pubitemid 18029298)
17. Travis, L. B. et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med. 340, 351-357 (1999). (Pubitemid 29090800)
18. Fanconi, G. Familial constitutional panmyelocytopathy, Fanconi's anemia (F. A.). I. Clinical aspects. Semin. Hematol. 4, 233-240 (1967).
19. Niedernhofer, L. J., Lalai, A. S. & Hoeijmakers, J. H. Fanconi anemia (cross)linked to DNA repair. Cell 123, 1191-1198 (2005). (Pubitemid 41821778)
20. Alpi, A. F. & Patel, K. J. Monoubiquitylation in the Fanconi anemia DNA damage response pathway. DNA Repair 8, 430-435 (2009).
21. Auerbach, A. D. A test for Fanconi's anemia. Blood 72, 366-367 (1988).
22. Raya, A. et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460, 53-59 (2009).
23. Rosenberg, P. S., Greene, M. H. & Alter, B. P. Cancer incidence in persons with Fanconi anemia. Blood 101, 822-826 (2003). (Pubitemid 36139345)
24. Butturini, A. et al. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 84, 1650-1655 (1994). (Pubitemid 24273037)
25. Faivre, L. et al. Association of complementation group and mutation type with clinical outcome in Fanconi anemia. Blood 96, 4064-4070 (2000).
26. Hirsch, B. et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 103, 2554-2559 (2004). (Pubitemid 38393006)
27. Reid, S. et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N. and predispose to childhood cancer. Nature Genet. 39, 162-164 (2007). (Pubitemid 46184345)
28. Alter, B. P., Rosenberg, P. S. & Brody, L. C. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J. Med. Genet. 44, 1-9 (2007). (Pubitemid 46142832)
29. Ali, A. M. et al. Identification and characterization of mutations in FANCL gene: a second case of Fanconi anemia belonging to FA-L complementation group. Hum. Mutat. 30, E761-E770 (2009).
30. Meetei, A. R. et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nature Genet. 37, 958-963 (2005). (Pubitemid 43086152)
31. Vaz, F. et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nature Genet. 42, 406-409 (2010).
32. Castella, M. et al. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood 117, 3759-3769 (2011).
33. Kutler, D. I. et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. Head Neck Surg. 129, 106-112 (2003). (Pubitemid 36070885)
34. Hofmann, W. K. & Koeffler, H. P. Myelodysplastic syndrome. Annu. Rev. Med. 56, 1-16 (2005). (Pubitemid 40299770)
35. Tischkowitz, M. & Winqvist, R. Using mouse models to investigate the biological and physiological consequences of defects in the Fanconi anaemia/ breast cancer DNA repair signalling pathway. J. Pathol. 9 Mar 2011 (doi:10.1002/path.2903).
36. Tonnies, H. et al. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 101, 3872-3874 (2003). (Pubitemid 36857860)
37. Quentin, S. et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 117, e161-e170 (2011).
38. Sala-Trepat, M., Boyse, J., Richard, P., Papadopoulo, D. & Moustacchi, E. Frequencies of HPRT- lymphocytes and glycophorin A variants erythrocytes in Fanconi anemia patients, their parents and control donors. Mutat. Res. 289, 115-126 (1993). (Pubitemid 23261952)
39. Jonnalagadda, V. S., Matsuguchi, T. & Engelward, B. P. Interstrand crosslink-induced homologous recombination carries an increased risk of deletions and insertions. DNA Repair 4, 594-605 (2005). (Pubitemid 40462047)
40. Hinz, J. M., Nham, P. B., Salazar, E. P. & Thompson, L. H. The Fanconi anemia pathway limits the severity of mutagenesis. DNA Repair 5, 875-884 (2006). (Pubitemid 44137487)
41. Ridet, A. et al. Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome. Cancer Res. 57, 1722-1730 (1997). (Pubitemid 27199666)
42. Bassal, M. et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J. Clin. Oncol. 24, 476-483 (2006). (Pubitemid 46630467)
43. Nijnik, A. et al. DNA repair is limiting for haematopoietic stem cells during ageing. Nature 447, 686-690 (2007). (Pubitemid 46889732)
44. -/- hematopoietic stem cells and decreases the risk of clonal evolution. Blood 101, 1299-1307 (2003). (Pubitemid 36182499)
45. Park, J. W. et al. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res. 70, 9959-9968 (2010).
46. Ceccaldi, R. et al. Spontaneous abrogation of the G2 DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J. Clin. Invest. 121, 184-194 (2011).
47. Wilke, C. M. et al. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum. Mol. Genet. 5, 187-195 (1996). (Pubitemid 26036914)
48. Kutler, D. I. et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia Patients. J. Natl Cancer Inst. 95, 1718-1721 (2003). (Pubitemid 37509080)
49. van Zeeburg, H. J. et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J. Natl Cancer Inst. 100, 1649-1653 (2008).
50. Ciccia, A., McDonald, N. & West, S. C. Structural and functional relationships of the XPF/MUS81 family of proteins. Annu. Rev. Biochem. 77, 259-287 (2008).
51. Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249-262 (2001). (Pubitemid 32206493)
52. Smogorzewska, A. et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129, 289-301 (2007). (Pubitemid 46584733)
53. Matsushita, N. et al. A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. Mol. Cell 19, 841-847 (2005). (Pubitemid 41316677)
54. Niedernhofer, L. J. The Fanconi anemia signalosome anchor. Mol. Cell 25, 487-490 (2007). (Pubitemid 46274451)
55. Kim, J. M., Kee, Y., Gurtan, A. & D'Andrea, A. D. Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. Blood 111, 5215-5222 (2008).
56. Remus, D. et al. Concerted loading of Mcm2-7 double hexamers around DNA during DNA replication origin licensing. Cell 139, 719-730 (2009).
57. Raschle, M. et al. Mechanism of replication-coupled DNA interstrand crosslink repair. Cell 134, 969-980 (2008).
58. Ciccia, A. et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol. Cell 25, 331-343 (2007). (Pubitemid 46206138)
59. Deans, A. J. & West, S. C. FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia. Mol. Cell 36, 943-953 (2009).
60. Singh, T. R. et al. MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM. Mol. Cell 37, 879-886 (2010).
61. Yan, Z. et al. A histone-fold complex and FANCM form a conserved DNA-remodeling complex to maintain genome stability. Mol. Cell 37, 865-878 (2010).
62. Pavri, R. et al. Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. Cell 125, 703-717 (2006). (Pubitemid 43732350)
63. van der Horst, A. et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nature Cell Biol. 8, 1064-1073 (2006).
64. Wang, X., Andreassen, P. R. & D'Andrea, A. D. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol. Cell. Biol. 24, 5850-5862 (2004). (Pubitemid 38787970)
65. Longerich, S., San Filippo, J., Liu, D. & Sung, P. FANCI binds branched DNA and is monoubiquitinated by UBE2T-FANCL. J. Biol. Chem. 284, 23182-23186 (2009).
66. Roques, C. et al. MRE11-RAD50-NBS1 is a critical regulator of FANCD2 stability and function during DNA double-strand break repair. EMBO J. 28, 2400-2413 (2009).
67. Kim, J. M. et al. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev. Cell 16, 314-320 (2009).
68. Smogorzewska, A. et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol. Cell 39, 36-47 (2010).
69. Kratz, K. et al. Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. Cell 142, 77-88 (2010).
70. MacKay, C. et al. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell 142, 65-76 (2010).
71. Moldovan, G.-L. et al. DNA polymerase POLN participates in cross-link repair and homologous recombination. Mol. Cell. Biol. 30, 1088-1096 (2010).
72. Woodward, A. M. et al. Excess Mcm2-7 license dormant origins of replication that can be used under conditions of replicative stress. J. Cell Biol. 173, 673-683 (2006). (Pubitemid 46165576)
73. Niedernhofer, L. J. et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444, 1038-1043 (2006). (Pubitemid 46018517)
74. Jaspers, N. G. et al. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am. J. Hum. Genet. 80, 457-466 (2007).
75. Stoepker, C. et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nature Genet. 43, 138-141 (2011).
76. Kim, Y. et al. Mutations of the SLX4 gene in Fanconi anemia. Nature Genet. 43, 142-146 (2011).
77. Hanada, K. et al. The structure-specific endonuclease MUS81-EME1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. EMBO J. 25, 4921-4932 (2006). (Pubitemid 44607036)
78. Svendsen, J. M. et al. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 138, 63-77 (2009).
79. Al-Minawi, A. Z. et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res. 37, 6400-6413 (2009).
80. Niedernhofer, L. J. et al. The structure-specific endonuclease ERCC1-XPF is required for targeted gene replacement in embryonic stem cells. EMBO J. 20, 6540-6549 (2001). (Pubitemid 33078726)
81. Wechsler, T., Newman, S. & West, S. C. Aberrant chromosome morphology in human cells defective for Holliday junction resolution. Nature 471, 642-646 (2011).
82. Smeaton, M. B. et al. Distortion-dependent unhooking of interstrand cross-links in mammalian cell extracts. Biochemistry 47, 9920-9930 (2008).
83. Fink, D. et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56, 4881-4886 (1996). (Pubitemid 26374423)
84. Zhao, J., Jain, A., Iyer, R. R., Modrich, P. L. & Vasquez, K. M. Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks. Nucleic Acids Res. 37, 4420-4429 (2009).
85. Ben-Yehoyada, M. et al. Checkpoint signaling from a single DNA interstrand crosslink. Mol. Cell 35, 704-715 (2009).
86. Sarkar, S., Davies, A. A., Ulrich, H. D. & McHugh, P. J. DNA interstrand crosslink repair during G1 involves nucleotide excision repair and DNA polymerase zeta. EMBO J. 25, 1285-1294 (2006).
87. Mu, D. et al. DNA interstrand cross-links induce futile repair synthesis in mammalian cell extracts. Mol. Cell. Biol. 20, 2446-2454 (2000). (Pubitemid 30152052)
88. Wong, B., Chen, S., Kwon, J. A. & Rich, A. Characterization of Z.-DNA as a nucleosome-boundary element in yeast Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 104, 2229-2234 (2007). (Pubitemid 46391380)
89. Ulrich, H. D. & Walden, H. Ubiquitin signalling in DNA replication and repair. Nature Rev. Mol. Cell Biol. 11, 479-489 (2010).
90. Munoz, I. M. et al. Coordination of structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair. Mol. Cell 35, 116-127 (2009).
91. Harder, H. C., Smith, R. G. & Leroy, A. F. Template primer inactivation by cis- and trans-dichlorodiammine platinum for human DNA polymerase α, β, and Rauscher murine leukemia virus reverse transcriptase, as a mechanism of cytotoxicity. Cancer Res. 36, 3821-3829 (1976).
92. Byun, T. S., Pacek, M., Yee, M. C., Walter, J. C. & Cimprich, K. A. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes Dev. 19, 1040-1052 (2005). (Pubitemid 40632450)
93. Lange, S. S., Takata, K. & Wood, R. D. DNA polymerases and cancer. Nature Rev. Cancer 11, 96-110 (2011).
94. Howlett, N. G., Harney, J. A., Rego, M. A., Kolling, F. W. & Glover, T. W. Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif. J. Biol. Chem. 284, 28935-28942 (2009).
95. Geng, L., Huntoon, C. J. & Karnitz, L. M. RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network. J. Cell Biol. 191, 249-257 (2010).
96. Masuda, Y., Ohmae, M., Masuda, K. & Kamiya, K. Structure and enzymatic properties of a stable complex of the human REV1 and REV7 proteins. J. Biol. Chem. 278, 12356-12360 (2003). (Pubitemid 36800219)
97. Hlavin, E. M., Smeaton, M. B., Noronha, A. M., Wilds, C. J. & Miller, P. S. Cross-link structure affects replication-independent DNA interstrand cross-link repair in mammalian cells. Biochemistry 49, 3977-3988 (2010).
98. Ho, T. V. & Scharer, O. D. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair. Environ. Mol. Mutagen. 51, 552-566 (2010).
99. Mirchandani, K. D., McCaffrey, R. M. & D'Andrea, A. D. The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. DNA Repair 7, 902-911 (2008).
100. Silver, D. P. et al. Efficacy of neoadjuvant nisplatin in triple-negative breast cancer. J. Clin. Oncol. 28, 1145-1153 (2010).
101. Cass, I. et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97, 2187-2195 (2003). (Pubitemid 36444059)
102. Wu-Baer, F., Lagrazon, K., Yuan, W. & Baer, R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J. Biol. Chem. 278, 34743-34746 (2003). (Pubitemid 37102231)
103. Jensen, R. B., Carreira, A. & Kowalczykowski, S. C. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467, 678-683 (2010).
104. Thorslund, T. et al. The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nature Struct. Mol. Biol. 17, 1263-1265 (2010).
105. Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R. & Bishop, D. K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of RAD51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275, 23899-23903 (2000). (Pubitemid 30624678)
106. Ito, M. et al. RAD51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J. Gene Med. 7, 1044-1052 (2005). (Pubitemid 41195066)
107. West, S. C. Molecular views of recombination proteins and their control. Nature Rev. Mol. Cell Biol. 4, 435-445 (2003). (Pubitemid 36648589)
108. Fong, P. C. et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
109. Gari, K., Dicaillet, C., Delannoy, M., Wu, L. & Constantinou, A. Remodeling of DNA replication structures by the branch point translocase FANCM. Proc. Natl Acad. Sci. USA 105, 16107-16112 (2008).
110. Koster, D. A., Palle, K., Bot., E. S., Bjornsti, M. A. & Dekker, N. H. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 448, 213-217 (2007). (Pubitemid 47067371)
111. Sogo, J. M., Lopes, M. & Foiani, M. Fork reversal and ssDNA accumulation at stalled replication forks owing to checkpoint defects. Science 297, 599-602 (2002). (Pubitemid 34815343)
112. Hashimoto, Y., Chaudhuri, A. R., Lopes, M. & Costanzo, V. RAD51 protects nascent DNA from MRE11-dependent degradation and promotes continuous DNA synthesis. Nature Struct. Mol. Biol. 17, 1305-1311 (2010).
113. Lio, Y. C., Schild, D., Brenneman, M. A., Redpath, J. L. & Chen, D. J. Human RAD51C deficiency destabilizes XRCC3, impairs recombination, and radiosensitizes S/G2-phase cells. J. Biol. Chem. 279, 42313-42320 (2004). (Pubitemid 39313680)
114. Lio, Y. C., Mazin, A. V., Kowalczykowski, S. C. & Chen, D. J. Complex formation by the human RAD51B and RAD51C DNA repair proteins and their activities in vitro. J. Biol. Chem. 278, 2469-2478 (2003). (Pubitemid 36801323)
115. Meindl, A. et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nature Genet. 42, 410-414 (2010).
116. Wu, L. & Hickson, I. D. The Bloom's syndrome helicase suppresses crossing over during homologous recombination. Nature 426, 870-874 (2003). (Pubitemid 38056876)
117. Wu, L. & Hickson, I. D. DNA helicases required for homologous recombination and repair of damaged replication forks. Annu. Rev. Genet. 40, 279-306 (2006). (Pubitemid 44956787)
118. Meetei, A. R. et al. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol. Cell. Biol. 23, 3417-3426 (2003). (Pubitemid 36539175)
119. Chaganti, R. S., Schonberg, S. & German, J. A manyfold increase in sister chromatid exchanges in Bloom's syndrome lymphocytes. Proc. Natl Acad. Sci. USA 71, 4508-4512 (1974).
120. Luo, G. et al. Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nature Genet. 26, 424-429 (2000).
121. Latt, S. A. Sister chromatid exchange formation. Annu. Rev. Genet. 15, 11-55 (1981).
122. Gottlieb, T. M. & Jackson, S. P. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 72, 131-142 (1993). (Pubitemid 23029700)
123. Lieber, M. R., Ma, Y., Pannicke, U. & Schwarz, K. Mechanism and regulation of human non-homologous DNA end-joining. Nature Rev. Mol. Cell Biol. 4, 712-720 (2003). (Pubitemid 37082186)
124. Frankenberg-Schwager, M. et al. Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae. Toxicology 212, 175-184 (2005). (Pubitemid 40981974)
125. Collins, A. R. Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics. Mutat. Res. 293, 99-118 (1993). (Pubitemid 23016403)
126. Pace, P. et al. Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Science 329, 219-223 (2010).
127. Adamo, A. et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol. Cell 39, 25-35 (2010).
128. Gurley, K. E. & Kemp, C. J. Synthetic lethality between mutation in ATM and DNA-PKcs during murine embryogenesis. Curr. Biol. 11, 191-194 (2001). (Pubitemid 32152105)
129. Ferreira, M. G. & Cooper, J. P. Two modes of DNA double-strand break repair are reciprocally regulated through the fission yeast cell cycle. Genes Dev. 18, 2249-2254 (2004). (Pubitemid 39209573)
130. Wang, H. et al. Non-homologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2. Cancer Res. 61, 270-277 (2001). (Pubitemid 32095727)
131. Yun, M. H. & Hiom, K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature 459, 460-463 (2009).
132. Blier, P. R., Griffith, A. J., Craft, J. & Hardin, J. A. Binding of Ku protein to DNA. Measurement of affinity for ends and demonstration of binding to nicks. J. Biol. Chem. 268, 7594-7601 (1993). (Pubitemid 23105662)
133. Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243-254 (2010).
134. Pierelli, L. et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J. Clin. Oncol. 17, 1288-1295 (1999). (Pubitemid 29162956)
135. Locke, F., Clark, J. I. & Gajewski, T. F. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother. Pharmacol. 65, 509-514 (2010).
136. Viale, A. et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 457, 51-56 (2009).
137. Selvakumaran, M., Pisarcik, D. A., Bao, R., Yeung, A. T. & Hamilton, T. C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63, 1311-1316 (2003). (Pubitemid 36348710)
138. Ferry, K. V., Hamilton, T. C. & Johnson, S. W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. 60, 1305-1313 (2000).
139. Taniguchi, T. et al. Disruption of the Fanconi anemia- BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Med. 9, 568-574 (2003). (Pubitemid 36597103)
140. Dabholkar, M. et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl Cancer Inst. 84, 1512-1517 (1992).
141. Tomoda, Y. et al. Functional evidence for EME1 as a marker of cisplatin resistance. Int. J. Cancer 124, 2997-3001 (2009).
142. Torres-Garcia, S. J., Cousieneau, L., Caplan, S. & Panasci, L. Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links. Biochem. Pharmacol. 38, 3122-3123 (1989). (Pubitemid 19222962)
143. Pietras, R. J. et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9, 1829-1838 (1994). (Pubitemid 24194147)
144. Goncalves, A. et al. High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study. Anticancer Res. 25, 663-667 (2005). (Pubitemid 40470079)
145. Hurley, J. et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J. Clin. Oncol. 24, 1831-1838 (2006). (Pubitemid 46638980)
146. Pegram, M. D. et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl Cancer Inst. 96, 759-769 (2004). (Pubitemid 38771821)
147. Sanchez, Y. et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497-1501 (1997). (Pubitemid 27449236)
148. Castedo, M. et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825-2837 (2004). (Pubitemid 38638845)
149. Reinhardt, H. C., Aslanian, A. S., Lees, J. A. & Yaffe, M. B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/ MK2 pathway for survival after DNA damage. Cancer Cell 11, 175-189 (2007). (Pubitemid 46209849)
150. Koniaras, K., Cuddihy, A. R., Christopoulos, H., Hogg, A. & O'Connell, M. J. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20, 7453-7463 (2001). (Pubitemid 33086904)
151. Eastman, A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry 22, 3927-3933 (1983). (Pubitemid 13035562)
152. Huang, H., Zhu, L., Reid, B. R., Drobny, G. P. & Hopkins, P. B. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270, 1842-1845 (1995). (Pubitemid 26007235)
153. Knox, R. J., Friedlos, F., Lydall, D. A. & Roberts, J. J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis- diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46, 1972-1979 (1986). (Pubitemid 16080411)
154. Vasey, P. A. et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96, 1682-1691 (2004). (Pubitemid 39585637)
155. Pasetto, L. M., D'Andrea, M. R., Rossi, E. & Monfardini, S. Oxaliplatin-related neurotoxicity: how and why? Crit. Rev. Oncol. Hematol. 59, 159-168 (2006). (Pubitemid 44094106)
156. Sternberg, C. N. et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68, 2-9 (2005). (Pubitemid 40675002)
157. Smith, J. W. et al. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. Breast Cancer Res. Treat. 118, 361-367 (2009).
158. Eckardt, J. R. et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J. Clin. Oncol. 27, 2046-2051 (2009).
159. Webba da Silva, M. et al. Solution structure of a DNA duplex containing mispair-aligned N4C-ethyl-N4C interstrand cross-linked cytosines. Biochemistry 41, 15181-15188 (2002).
160. Morley, A. & Stohlman, F. Jr. Cyclophosphamide-induced cyclical neutropenia. An animal model of a human periodic disease. N. Engl. J. Med. 282, 643-646 (1970).
161. Facon, T. et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370, 1209-1218 (2007). (Pubitemid 47516593)
162. Rai, K. R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1750-1757 (2000).
163. Ahn, J. B. et al. Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer. Am. J. Clin. Oncol. 23, 622-628 (2000).
164. Spielmann, H. P., Dwyer, T. J., Hearst, J. E. & Wemmer, D. E. Solution structures of psoralen monoadducted and cross-linked DNA oligomers by NMR spectroscopy and restrained molecular dynamics. Biochemistry 34, 12937-12953 (1995).
165. Stoll, D. B., Lavin, P. T. & Engstrom, P. F. Hematologic toxicity of cisplatin and mitomycin in combination for squamous cell carcinoma of esophagus. Am. J. Clin. Oncol. 8, 231-234 (1985). (Pubitemid 16256998)
166. Hussain, S. A. et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br. J. Cancer 90, 2106-2111 (2004). (Pubitemid 38869713)
167. Wolff, K. Side-effects of psoralen photochemotherapy (PUVA). Br. J. Dermatol. 122, 117-125 (1990). (Pubitemid 20176070)
168. Querfeld, C. et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch. Dermatol. 141, 305-311 (2005). (Pubitemid 40365446)
169. Janjigian, Y. Y. et al. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother. Pharmacol. 65, 833-838 (2010).